Granuloma Annulare Induced by Adalimumab.
- Author:
Young Jae OH
1
;
Won Jun CHOI
;
Joo Yeon KO
;
Young Suck RO
Author Information
1. Department of Dermatology, Hanyang University College of Medicine, Seoul, Korea. drko0303@hanyang.ac.kr
- Publication Type:Case Report
- Keywords:
Adalimumab;
Granuloma annulare;
TNF-alpha inhibitor
- MeSH:
Antibodies, Monoclonal, Humanized;
Arthritis, Psoriatic;
Arthritis, Rheumatoid;
Crohn Disease;
Granuloma;
Granuloma Annulare;
Humans;
Korea;
Necrosis;
Pityriasis Rosea;
Spondylitis, Ankylosing;
Still's Disease, Adult-Onset;
Tumor Necrosis Factor-alpha;
Adalimumab
- From:Korean Journal of Dermatology
2011;49(7):656-659
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Adalimumab is the first fully humanized monoclonal anti-tumor necrosis factor alpha (TNF-alpha) antibody. This drug has been shown to be of benefit in patients with inflammatory diseases in which TNF-alpha is involved, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. As the use of adalimumab is becoming more widespread, cutaneous side effects are being increasingly reported. Various dermatologic adverse events have been reported in the literature, including injection site reactions, psoriasis-like eruption and pityriasis rosea. Herein, we describe a case of GA associated with adalimumab treatment for adult-onset Still's disease, which has not been reported in Korea.
